Most Read Articles
Pearl Toh, 6 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
24 Mar 2020
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.

Low rheumatoid factor at CZP discontinuation predicts remission maintenance in RA

05 Mar 2020

Rheumatoid arthritis (RA) patients who exhibit low rheumatoid factor (RF), as well as low disease activity, following treatment with certolizumab pegol (CZP) plus methotrexate (MTX) may be able to discontinue CZP without the increased risk of loss of remission, a recent study has shown.

Researchers performed a posthoc analysis of the C-OPERA cohort of MTX‐naïve early RA patients with poor prognostic factors. They included 159 patients randomized to CZP + MTX (n=159) and 157 to placebo plus MTX; those who completed the 1‐year treatment period received MTX alone in the second year (CZP + MTX→MTX, n=108; placebo + MTX→MTX, n=71).

Multiple regression analysis was used to examine the association between factors at baseline or at discontinuation of CZP and clinical/radiographic outcomes. Predictive value cutoffs were calculated via receiver operating characteristic analysis.

Male sex and low baseline Disease Activity Score of 28 joints-erythrocyte sedimentation rate (DAS28‐ESR) correlated with simple disease activity index (SDAI) remission (≤3.3), whereas high baseline DAS28‐ESR and modified total Sharp score (mTSS) correlated with clinically relevant radiographic progression (yearly progression mTSS > 3) at week 104 in both treatment arms.

Low DAS28‐ESR (<2.1) and RF (<74 IU/mL) at discontinuation of CZP predicted SDAI remission at week 104. SDAI remission was also noted in 75.0 percent (42/56) of patients with low DAS28‐ESR and RF at discontinuation, as opposed to only 15.4 percent (2/13) of those with high DAS28‐ESR and RF.

The present data show that disease activity and joint damage at the start of treatment may be predictive of long‐term outcomes in patients treated with optimized MTX plus CZP, according to the researchers. “Therefore, patients with poor prognostic factors may benefit from initial aggressive treatment with CZP and MTX.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 6 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
24 Mar 2020
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.